IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9717730 B1

PDFFull Text
Date of Patent:
Aug. 01, 2017

Filed:

Feb. 05, 2016

Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use

Applicant:

Genentech, Inc., South San Francisco, CA (US);

Inventors:

Kui Lin, South San Francisco, CA (US);

Michelle Nannini, South San Francisco, CA (US);

Elizabeth Punnoose, South San Francisco, CA (US);

Deepak Sampath, South San Francisco, CA (US);

Jeffrey Wallin, South San Francisco, CA (US);

Premal Patel, South San Francisco, CA (US);

Assignee:

GENENTECH, INC., South San Francisco, CA (US);

Attorney:

Viksnins Harris & Padys PLLP

Primary Examiner:

Peter J Reddig

Assistant Examiner:

Kauser Akhoon

Int. Cl.
CPC ...
A61K 31/00 (2006.01); A61K 31/4745 (2006.01); A61K 31/495 (2006.01); C07D 239/70 (2006.01); A61K 31/517 (2006.01); A61K 31/437 (2006.01); A61K 31/496 (2006.01); A61K 31/58 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/4188 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/704 (2006.01); A61K 39/395 (2006.01); C07D 403/12 (2006.01); A61K 31/436 (2006.01); A61K 31/138 (2006.01); A61K 31/4166 (2006.01); A61K 31/555 (2006.01); A61K 31/7068 (2006.01); C07K 16/40 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/517 (2013.01); A61K 31/138 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/4166 (2013.01); A61K 31/4188 (2013.01); A61K 31/436 (2013.01); A61K 31/437 (2013.01); A61K 31/4745 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 31/58 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 39/3955 (2013.01); C07D 239/70 (2013.01); C07D 403/12 (2013.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01);
Abstract

The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R, R, R, R, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

Find Patent Forward Citations

Loading…